Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Cash from Investing Activities: 2020-2024

Historic Cash from Investing Activities for Therapeutics (RAPT) over the last 5 years, with Dec 2024 value amounting to -$843,000.

  • Therapeutics' Cash from Investing Activities fell 104.08% to -$843,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $52.7 million, marking a year-over-year decrease of 49.39%. This contributed to the annual value of $52.7 million for FY2024, which is 49.39% down from last year.
  • Per Therapeutics' latest filing, its Cash from Investing Activities stood at -$843,000 for Q4 2024, which was down 104.57% from $18.4 million recorded in Q3 2024.
  • In the past 5 years, Therapeutics' Cash from Investing Activities registered a high of $32.4 million during Q2 2023, and its lowest value of -$63.7 million during Q2 2021.
  • In the last 3 years, Therapeutics' Cash from Investing Activities had a median value of $18.8 million in 2024 and averaged $9.3 million.
  • As far as peak fluctuations go, Therapeutics' Cash from Investing Activities plummeted by 1,437.17% in 2021, and later soared by 410.16% in 2023.
  • Over the past 5 years, Therapeutics' Cash from Investing Activities (Quarterly) stood at $15.5 million in 2020, then crashed by 202.56% to -$15.9 million in 2021, then crashed by 159.69% to -$41.3 million in 2022, then spiked by 150.01% to $20.6 million in 2023, then plummeted by 104.08% to -$843,000 in 2024.
  • Its last three reported values are -$843,000 in Q4 2024, $18.4 million for Q3 2024, and $19.2 million during Q2 2024.